CA2446391A1 - Method for inducing t cells regulator with cd47 ligands - Google Patents
Method for inducing t cells regulator with cd47 ligands Download PDFInfo
- Publication number
- CA2446391A1 CA2446391A1 CA002446391A CA2446391A CA2446391A1 CA 2446391 A1 CA2446391 A1 CA 2446391A1 CA 002446391 A CA002446391 A CA 002446391A CA 2446391 A CA2446391 A CA 2446391A CA 2446391 A1 CA2446391 A1 CA 2446391A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- tas
- regulatory
- activity
- treg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 36
- 239000003446 ligand Substances 0.000 title claims abstract description 13
- 230000001939 inductive effect Effects 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 13
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims abstract description 30
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 24
- 210000003289 regulatory T cell Anatomy 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 31
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract description 13
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000014509 gene expression Effects 0.000 abstract description 6
- 230000006698 induction Effects 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract description 4
- 108060008245 Thrombospondin Proteins 0.000 abstract description 4
- 102000002938 Thrombospondin Human genes 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 abstract description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 abstract description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract description 3
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000003252 repetitive effect Effects 0.000 abstract description 3
- 102000004127 Cytokines Human genes 0.000 abstract description 2
- 108090000695 Cytokines Proteins 0.000 abstract description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract description 2
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 208000037976 chronic inflammation Diseases 0.000 abstract description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract description 2
- 230000016396 cytokine production Effects 0.000 abstract description 2
- 208000024908 graft versus host disease Diseases 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 abstract 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 abstract 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 abstract 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 abstract 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 101150089023 FASLG gene Proteins 0.000 abstract 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 abstract 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 abstract 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 abstract 1
- 230000017274 T cell anergy Effects 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000009456 molecular mechanism Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 15
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010017447 4N1K peptide Proteins 0.000 description 1
- 102100024092 Aldo-keto reductase family 1 member C4 Human genes 0.000 description 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- -1 CD45RO Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150015687 CDA7 gene Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Naturally occurring CD4+CD25+T regulatory cells (Treg) activily participate to the mechanisms of peripheral tolerance by negatively regulating autoimmunity.
However, the molecular mechanisms of in vivo induction of T reg remain largely unknown.
Regulatory T cells (Tr1) can be generated in vitro from human naive T cells by repetitive stimulation with immature or IL-10-treated DC. We previously reported that CD47 ligation by either CD47 mAb or a peptide of its natural ligand, i.c thrombospondin, induced naïve T cell anergy. Herein, we demonstrate that the CD47 mAb- induced anergic T cells were actively suppressing the proliferation and cytokine production of syngeneic effector T
cells. T anergic/suppressors cells (Tas) produced little or no cytokine. The suppressive function required physical contact with the responder T cells and was IL-10 and TGF-.beta.
independent. Tas displayed :1) increased expression of CTLA-4, OX40 and GITR;
2) decreased levels of CD40L and CD28 and 3) similar levels of FAS, FASL, CCR4 and CCR7 and CD25 compared to effector T cells. Both CD4+ and CD8+Tas suppressed effector T cells proliferation and none of them regulated DC maturation. Our findings demonstrate that ligation of an endogenous receptor, i.e CD47, on naive cells generates a distinct type of regulatory T cells (Tas) which produce no IL-10 but share phenotypic and functional features with both Treg and Tr1 described in human and mice. TAS
may be re-infused to patients suffering from a large variety of chronic inflammatory diseases, graft versus host disease, graft rejection and allergic diseases. Compounds inducing in vivo the activity of TAS may be used to treat the same patients.
However, the molecular mechanisms of in vivo induction of T reg remain largely unknown.
Regulatory T cells (Tr1) can be generated in vitro from human naive T cells by repetitive stimulation with immature or IL-10-treated DC. We previously reported that CD47 ligation by either CD47 mAb or a peptide of its natural ligand, i.c thrombospondin, induced naïve T cell anergy. Herein, we demonstrate that the CD47 mAb- induced anergic T cells were actively suppressing the proliferation and cytokine production of syngeneic effector T
cells. T anergic/suppressors cells (Tas) produced little or no cytokine. The suppressive function required physical contact with the responder T cells and was IL-10 and TGF-.beta.
independent. Tas displayed :1) increased expression of CTLA-4, OX40 and GITR;
2) decreased levels of CD40L and CD28 and 3) similar levels of FAS, FASL, CCR4 and CCR7 and CD25 compared to effector T cells. Both CD4+ and CD8+Tas suppressed effector T cells proliferation and none of them regulated DC maturation. Our findings demonstrate that ligation of an endogenous receptor, i.e CD47, on naive cells generates a distinct type of regulatory T cells (Tas) which produce no IL-10 but share phenotypic and functional features with both Treg and Tr1 described in human and mice. TAS
may be re-infused to patients suffering from a large variety of chronic inflammatory diseases, graft versus host disease, graft rejection and allergic diseases. Compounds inducing in vivo the activity of TAS may be used to treat the same patients.
Description
A METHOD FOR THE INDUCTION OF HUNAN REGULATORY T CELLS BY
A MONOCLONAL ANTIBODY TO CD4~ ANTIGEN
BACKGROUND OF THE INVENT ION
The role o.f the immune system is to maintain the homeostasis of the organism and protect against dangerous components of the environment, mainly micro-organisms. In some situations, the immune response ( IR) is undesired and harmful ; for example it may reject allograft or mediate graft versus host disease (CTVHD) after allogenic bone marrow transplantation. In other cases, the IR may be aberrant and generate chronic inflammatory diseases. The latter results from a T cell-dependent IR against :1) self antigens (occurring in conditions like autoimmune diseases, namely multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosous) :2) innocuous and ubiquitous components of the environment such as airborne antigens or food (occurring in conditions like allergic diseases, namely asthma, allergic rhinitis, atopic eczema) :3) commensal and innocuous bacteria (occurring in conditions like chronic, inflammatory bowel diseases).
The failure of normal individuals to respond to self Ag and develop autoimmune disease results from both central tolerance (intra-thymic deletion of auto-reactive T
lymphocytes) and peripheral tolerance ( clonal deletion, anergy of auto-reactive cells or suppression of their activity by regulatory T cells (Treg). There is increasing eW dence, derived mainly from animal models, that Treg also prevent and control allergic diseases and chronic inflammatory bowel diseases. Treg are also involved in long term transplantation tolerance and prevent experimental CiVH.
Regulatory T cells, specialized in tlic suppr.-.ssiom of the imnunc response arc heterogeneous and may belong to the CD4+, CD8 '- or NKT cell lineage. Treg control the response to self antigens, tumor antigens, allogeneic cells, innocuous airborne or dietary Ags, commensal or pathogenic bacteria. The most extensively investigated Treg are the naturally occurring CD4+ CD25+ T cells and the induced Trl (Type 1 regulatory T cells).
Naturally occurring CD4* CD25k T cells are generated in the thymus where they are selected following high affinity interaction with still undefined self ligand(s). CD4+
_1_ CD25~ T cells constitute 5-10% of the normal peripheral CD4F T cell repertoia~e of mice and humans. They are long-lived and display the phenotype of previously activated T
cells; for example, human CD4+ CD25+ T cells are CD45R0+ and express increased levels of HLA-DR and CTLA-4. Gene expression analysis of mouse CD4+ CD25+ Treg confirmed that they have been recently activated and revealed that they constitutively express three members of the TNF-R superfamily (i.e.OX40, 4-1BB and CiITR) that are transiently expressed on au~tivated T cells. CD25+ CD4+ T cells are anergic, and in vitt°o, , they inhibit the response of CD25- T cells by blocking the transcription of IL-2 gene in CD4+ T cells amd the expression of IL-2 R cc chain on CD8+ T cells. he vztr~o, the suppression is contact-dependent and not inhibited by neutralizing Abs to IL-10 or TGF-(3; however, i~ vivo,the suppressive activity of CD25+ CD4+ T cells is overcome by neutralization of TCTF-(3 or IL-10. Although human and mouse CD4+ CD25~ T
cells wer a reported to express membrane bound TGF-[3 on their surface, the role of this cytokine in mediating the suppressive activity has been challenged. Naturally occurring Treg may also be CD25-; these are derived from mature naive CD4 T cells outside the thymus (without the help of CD25+ Treg) and display similar phenotypic and functional features as CD25+ Treg.
The term Trl was initially used to describe Treg generated in vitro a$er repetitive stimulation ofnaive T cells in the presence of IL-10. Tr1 cells suppressed in vitro and in viva Thl and Th2 immune responses and their suppressive activity was ascribed to their secretion of IL-10 and TGF-(3. Different methods have been developed to generate Trl cells z~ vitro including: (1) the addition of IFN-a, to T cells activated in the presence of IL-10,(2) the ligation of either CD2, 4C8 or CD46 on TCR-activated T cells in the absence of other co stimulatory signal, (3)T cell activation in the presence of 1,25(OH) ~Vit D3 and dexamethasone ,(4) repetitive stimulation of naive T cells by immature allogeneic DCs and(5) naive T cell activation by dendritic cells pre-incubated with the heavy chain of ferritin t~Uith the exception of those induced b:y naive T cell activation in the presence of immunosuppressive agents and neutralizing vAbs to IFN-y and IL-4, the Trl described in the above studies were anergic and produced variable levels of IFN-y and IL-5, in addition to IL-10 and TGF-(3. In viva, Trl cells may be induced by _2_ infectious agents such as Bordetella Pertussis, Mycobacterium tuberculosis, and Leishmania major. The lack of pro inflammatory immune response to inhaled protein antigens was ascribed to the development of Ag-specific Trl cells. The latter were generated during the interaction between Ag-specific naive T cells and airway DC by mechanisms involving ICOS/ICOSL interactions and IL-10 production by DC.
Similarly tolerance to dietary Ags and commensal intestinal bacteria is mediated by a subset of Treg producing high levels of TGF-~i known as Th3 cell.
The induction of regulatory T cells presents a clinical potential. Agonistic or antagonistic compounds for such induction ~~ill enhance or suppress the activity of Suppressor T cells.
SUMMARY OF THE INV'ENTif?N
We have succeeded in developing an in vitro or ex vivo model allowing the induction of a novel type of regulatory T cells, named TAS. Unlike the naturally occurring CD25~ CD4+
T cells, TAS may be CD4+ or CD8+ and unlike the Trl cells they suppress by a contact-dependent but IL-lU and TGF-(3-independent mechanism . TAS are generated by engaging the CD47 Ag at the time of T cell activation by mitogens or pol.yclonal activators.
CD47 Ag, also known as Integrin Associated Protein (IAP), is a widely expressed multispan transmembrane protein, which is physically and functionally associated with ccv(33 integrin, the vitronectin receptor. CD47 has also been implicated in leukocyte transendothelial migration. Its recently described natural ligand, thrombospondin ('fSP), is an homotrimeric extracellular matrix protein (ECM) which is produced not only by platelets but also by monocytes and alveolar macrophages. Thrombospondin is tz~ansiently expressed at high concentration in damaged and inflamed tissues.
We recently suggested a potential role for TSP or CD47 in ianmune regulation by the finding that they regulate the in vitro production and response to IL-12. Engagement of CD47 by either mAb, TSP or 4N 1 K (a peptide of the C-terminal domain of TSP selectively binding CDA7), inhibited IL-12 release by htunan rrionocy~es. The suppression was selective for IL-12 and occurred following T cell-dependent or -independent stimulation of monocytes. We have next ohserved that CD47 engagement in primary cultures of cord blood mononuclear cells inhibits IL-12 driven Thl cell development, as revealed by the cy~tokine secretion profile at restimulation and IFN-y production at the single cell level.
Ligation of CD47 does not deviate the phenotype of IL-I2-primed cells from 'fhl to Th2, however it does not affect IL-4-induced Th2 cell development. CD47 mAb, its Fab'2 fragments or the synthetic peptide 4N1K, corresponding to the CD47-binding site of thrombospondin, all display the same activity and inhibit the production of IFN-'y and IL-2 in primary cultures as well as the expression of IL-12R(32 chaW . Inclusion of exogenous IL-2 at priming coweets IL-I2R expression at priming and at restimulation as ~~ell as the inhibition of Thl cell development.
It is an object of this invention to provide a method for interacting or interfering with the development of a disease or condition involving the activity of Suppressor T
cells, in a patient, which comprises the steps of - inducing ex vivo the number and,~or activity of human regulatory T Lens by stimulating blood lymphocyrtes in the presence of a CD47 ligand~ and - reinfusing the induced human regulatory T cells to the patient.
The CD47 ligand may be an agonistic or antagonistic thereof. More specifically, the CD47 ligand that has induced the number and activity of Suppressor T cells is a CD47 monoclonal Antibody, namely the Antibody produced by the hybridoma deposited at the ATCC under accession number B6H121Hb9771 .
This method will result in the tr eatment of diseases or conditions wherein Suppressor T
cells activity is to be enhanced or inriibited. tn trie first case, auto immune diseases, allergic diseases and inflammatory diseases would benefit i~rom such inhibition.
Enhancing the activity of Suppressor T cells would also result in recipient tolerance to a grafted tissue. In the latter case, inhibiting the activity of Supxrressor T
cells would result in greater neutralisation of infectious agents.
_q._ Another object of this invention is a method of screening a vaxiety of compounds, in order to find agonistic and antagonistic compounds capable of enhancing or suppressing the activity of Suppressor T cells. Agonistic and antagonistic compounds would represent alternatives to the monoclonal Antibody to CD47, for example.
DESCRIPTION OF THE INVENTION
This invention will be described hereinbelow, by reference to specific examples, enbodiements and figures, the propose of which is to illustrate the invention rather than to limit its scope.
BRIEF DESCRIPTION OF THE FIGURES
In fig.lA, cells were recovered after 3 days of stimulation., washed , stained with the fluorescent vital dye CFSE and cultured for another 5 days in culture medium supplemented with IL-2. Cells wore then washed and analyzed by flow cytometry . A.s seen, anti-CD47-treated cells (TAS) proliferate much less than the control cells (ThU) activated in the presence of control antibody. Tas and Th0 are comprised of >95% CD3+~
T cells, of which GU% are CD4+ and 40% CDS+.
In fig.l8 and C, TAS and Th0 were expanded in II -2-supplemented medium for 5 days, washed and restimulated with anti-CD3 mAb immobilized on L cells cotransfected vrith human CD32 B7 antigens. After 3 days of culture,the proliferative response was measured by determining the tritiated thymidine uptakes whereas the secretion of IL-10 and TCiF-(3 were measured by ELISA. As seen, TAS proliferate and secrete much less IL-lU than Th0 cells, TAS and ThU produce similar and very low levels of Tf'tF-(3.
Fig.ID, TAS were co-cultured with ThU cells at a 1/1 ratio and the mixture was stimulated for 3 days with graded doses of anti-CD3 mAb (lUU, SU and lU ng%ml) 111i111V17111GG1~ Vll CD32 L37 L 11~.11a1GC:~il.il~J. tia ~GGll, ~rLW J
gJV1.c11Lly L11111171L Lilt ~Jd VIl.rGlA.d.lVd1 and the production of IFN-y by ThU cells.
Fis.lE shov.~s that the suppressive effect ofTAS is dose-dependent.
Fig.2 demonstrates that TAS inhibit the proliferative ( tritiated thymidine uptake) and the cytokine production by Th2 cells (IL-4) (Fig.2A). and Thl cells (Fig.2B and C). Fig.2B
and C also show that the suppressive activity of TAS is not observed if TAS
are physically separated from their target Th0 or Th1 by a semi-permeable membrane.This indicates that the suppressive activity of TAS is contact-dependant and not mediated by soluble factors. Moreover the suppressive activity of TAS is not overcome by blocking anti-IL10 and anti-TGF-(3 mAbs (not shown) Fig.3 shows the phenotype of TAS compared to that of Th0 ~a.s determined by by 2 to 4 color analysis by means of a FACSCALIBUR. TAS and Th0 cells display similar levels of CD25, CD45RO,CD3, CD4, CDR, CD28 and CD47" TAS express higher levels of OX40, GITR and CTLA-4. The proportion of cells expressing membrane bound TGF-(3 is slightly higher in TAS. About 50% of TAS co-express O~i40, GITR and CTLA-4 as compared to about 30% of Th0 cells on which these molecules are also expressed at lower levels-In the experiments summarized in figures 1 to 3, umbilical cord blood mononuclear cells were stimulated in standard conditions with a polyc,lonal activator such as Phytohemaglutinin (PHA) in the presence of a monoclonal antibody to CD47 or a control antibody.
EXAMPLES
Example 1. TAS are prepared from the peripheral blood lymphocytes of a patient with one of the above mentioned inflammatory diseases. The cells are prepared and cultured using conditions similar to those described in Avice et ai. (J.
Irnrnuno1.,2001, 167 : 2459-2468). 10 ~ to 10 g TAS are then re-infused intravenously in the patient. In this example, peripheral blood mononuclear cells are isolated from the patient by conventional fractionation method , Cells are then ac,~tivated for a tear days with a classical T cell activator, such as PHA in the presence of a CD47 ligand, such as for example anti CD47 mAb; cells are then expanded in IL-2 supplemented medium to obtain sufficient number of cells. TAS so prepared are washed and resuspended in a physiological solution before being infi~sed into the patient. The procedure may be repeated as often as necessary.
Example2. The molecular signature of TAS cells, i.e. the genes specifically expressed in these cells and induced by CD47 ligand ,are used to screen any compound with potential application in the treatment of inflammatory disease, CTVHD, graft rejection or cancer.
The genes selectively expressed in TAS cells will be identified on highly purified preparations TAS by means of conventional DNA microarrays.
If a given compound activates a signature gene of TAS, the compound will be examined and tested for its activity in in:f(ammatory diseases ( see above), CrVHD and grad rejection. Such a compound should not be used for the treatment of cancer patient as it will increase the activity of Treg inhibiting the anti-tumor immune response.
Compound inhibiting the expression of TAS signature gene may tested and used as irnmunostimulant to enhance the immune response against cancer cells or any vaccine.
The TAS may be used in assays as they are in a whole blood sample, or in a purified or semi-purified .form e.g. blood cells of a sample would be enriched in CD47 cells, by induction and~or b~~ retention on :ua affinity medium. Such techniques well lrmot~~n in the art, are easily adaptable toCD47 cells. Recombinant cells engineered to express C.D47 could also be used to screen ligands simply having affinity to CD47. A
potentially clinical compound will be developed for its capacity to be an agonistic or an antaganistic to CD47 cell activity.
The invention being hereinabove described, it will be obvious that the same be varied in many ways. Those skilled in the art recognise that other and further changes and modifications may be made thereto without departing from the spirit of the invention, and _7_ it is intended that all such changes and modifications fall within the scope of the invention, as defined in the appended claims.
_g_
A MONOCLONAL ANTIBODY TO CD4~ ANTIGEN
BACKGROUND OF THE INVENT ION
The role o.f the immune system is to maintain the homeostasis of the organism and protect against dangerous components of the environment, mainly micro-organisms. In some situations, the immune response ( IR) is undesired and harmful ; for example it may reject allograft or mediate graft versus host disease (CTVHD) after allogenic bone marrow transplantation. In other cases, the IR may be aberrant and generate chronic inflammatory diseases. The latter results from a T cell-dependent IR against :1) self antigens (occurring in conditions like autoimmune diseases, namely multiple sclerosis, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosous) :2) innocuous and ubiquitous components of the environment such as airborne antigens or food (occurring in conditions like allergic diseases, namely asthma, allergic rhinitis, atopic eczema) :3) commensal and innocuous bacteria (occurring in conditions like chronic, inflammatory bowel diseases).
The failure of normal individuals to respond to self Ag and develop autoimmune disease results from both central tolerance (intra-thymic deletion of auto-reactive T
lymphocytes) and peripheral tolerance ( clonal deletion, anergy of auto-reactive cells or suppression of their activity by regulatory T cells (Treg). There is increasing eW dence, derived mainly from animal models, that Treg also prevent and control allergic diseases and chronic inflammatory bowel diseases. Treg are also involved in long term transplantation tolerance and prevent experimental CiVH.
Regulatory T cells, specialized in tlic suppr.-.ssiom of the imnunc response arc heterogeneous and may belong to the CD4+, CD8 '- or NKT cell lineage. Treg control the response to self antigens, tumor antigens, allogeneic cells, innocuous airborne or dietary Ags, commensal or pathogenic bacteria. The most extensively investigated Treg are the naturally occurring CD4+ CD25+ T cells and the induced Trl (Type 1 regulatory T cells).
Naturally occurring CD4* CD25k T cells are generated in the thymus where they are selected following high affinity interaction with still undefined self ligand(s). CD4+
_1_ CD25~ T cells constitute 5-10% of the normal peripheral CD4F T cell repertoia~e of mice and humans. They are long-lived and display the phenotype of previously activated T
cells; for example, human CD4+ CD25+ T cells are CD45R0+ and express increased levels of HLA-DR and CTLA-4. Gene expression analysis of mouse CD4+ CD25+ Treg confirmed that they have been recently activated and revealed that they constitutively express three members of the TNF-R superfamily (i.e.OX40, 4-1BB and CiITR) that are transiently expressed on au~tivated T cells. CD25+ CD4+ T cells are anergic, and in vitt°o, , they inhibit the response of CD25- T cells by blocking the transcription of IL-2 gene in CD4+ T cells amd the expression of IL-2 R cc chain on CD8+ T cells. he vztr~o, the suppression is contact-dependent and not inhibited by neutralizing Abs to IL-10 or TGF-(3; however, i~ vivo,the suppressive activity of CD25+ CD4+ T cells is overcome by neutralization of TCTF-(3 or IL-10. Although human and mouse CD4+ CD25~ T
cells wer a reported to express membrane bound TGF-[3 on their surface, the role of this cytokine in mediating the suppressive activity has been challenged. Naturally occurring Treg may also be CD25-; these are derived from mature naive CD4 T cells outside the thymus (without the help of CD25+ Treg) and display similar phenotypic and functional features as CD25+ Treg.
The term Trl was initially used to describe Treg generated in vitro a$er repetitive stimulation ofnaive T cells in the presence of IL-10. Tr1 cells suppressed in vitro and in viva Thl and Th2 immune responses and their suppressive activity was ascribed to their secretion of IL-10 and TGF-(3. Different methods have been developed to generate Trl cells z~ vitro including: (1) the addition of IFN-a, to T cells activated in the presence of IL-10,(2) the ligation of either CD2, 4C8 or CD46 on TCR-activated T cells in the absence of other co stimulatory signal, (3)T cell activation in the presence of 1,25(OH) ~Vit D3 and dexamethasone ,(4) repetitive stimulation of naive T cells by immature allogeneic DCs and(5) naive T cell activation by dendritic cells pre-incubated with the heavy chain of ferritin t~Uith the exception of those induced b:y naive T cell activation in the presence of immunosuppressive agents and neutralizing vAbs to IFN-y and IL-4, the Trl described in the above studies were anergic and produced variable levels of IFN-y and IL-5, in addition to IL-10 and TGF-(3. In viva, Trl cells may be induced by _2_ infectious agents such as Bordetella Pertussis, Mycobacterium tuberculosis, and Leishmania major. The lack of pro inflammatory immune response to inhaled protein antigens was ascribed to the development of Ag-specific Trl cells. The latter were generated during the interaction between Ag-specific naive T cells and airway DC by mechanisms involving ICOS/ICOSL interactions and IL-10 production by DC.
Similarly tolerance to dietary Ags and commensal intestinal bacteria is mediated by a subset of Treg producing high levels of TGF-~i known as Th3 cell.
The induction of regulatory T cells presents a clinical potential. Agonistic or antagonistic compounds for such induction ~~ill enhance or suppress the activity of Suppressor T cells.
SUMMARY OF THE INV'ENTif?N
We have succeeded in developing an in vitro or ex vivo model allowing the induction of a novel type of regulatory T cells, named TAS. Unlike the naturally occurring CD25~ CD4+
T cells, TAS may be CD4+ or CD8+ and unlike the Trl cells they suppress by a contact-dependent but IL-lU and TGF-(3-independent mechanism . TAS are generated by engaging the CD47 Ag at the time of T cell activation by mitogens or pol.yclonal activators.
CD47 Ag, also known as Integrin Associated Protein (IAP), is a widely expressed multispan transmembrane protein, which is physically and functionally associated with ccv(33 integrin, the vitronectin receptor. CD47 has also been implicated in leukocyte transendothelial migration. Its recently described natural ligand, thrombospondin ('fSP), is an homotrimeric extracellular matrix protein (ECM) which is produced not only by platelets but also by monocytes and alveolar macrophages. Thrombospondin is tz~ansiently expressed at high concentration in damaged and inflamed tissues.
We recently suggested a potential role for TSP or CD47 in ianmune regulation by the finding that they regulate the in vitro production and response to IL-12. Engagement of CD47 by either mAb, TSP or 4N 1 K (a peptide of the C-terminal domain of TSP selectively binding CDA7), inhibited IL-12 release by htunan rrionocy~es. The suppression was selective for IL-12 and occurred following T cell-dependent or -independent stimulation of monocytes. We have next ohserved that CD47 engagement in primary cultures of cord blood mononuclear cells inhibits IL-12 driven Thl cell development, as revealed by the cy~tokine secretion profile at restimulation and IFN-y production at the single cell level.
Ligation of CD47 does not deviate the phenotype of IL-I2-primed cells from 'fhl to Th2, however it does not affect IL-4-induced Th2 cell development. CD47 mAb, its Fab'2 fragments or the synthetic peptide 4N1K, corresponding to the CD47-binding site of thrombospondin, all display the same activity and inhibit the production of IFN-'y and IL-2 in primary cultures as well as the expression of IL-12R(32 chaW . Inclusion of exogenous IL-2 at priming coweets IL-I2R expression at priming and at restimulation as ~~ell as the inhibition of Thl cell development.
It is an object of this invention to provide a method for interacting or interfering with the development of a disease or condition involving the activity of Suppressor T
cells, in a patient, which comprises the steps of - inducing ex vivo the number and,~or activity of human regulatory T Lens by stimulating blood lymphocyrtes in the presence of a CD47 ligand~ and - reinfusing the induced human regulatory T cells to the patient.
The CD47 ligand may be an agonistic or antagonistic thereof. More specifically, the CD47 ligand that has induced the number and activity of Suppressor T cells is a CD47 monoclonal Antibody, namely the Antibody produced by the hybridoma deposited at the ATCC under accession number B6H121Hb9771 .
This method will result in the tr eatment of diseases or conditions wherein Suppressor T
cells activity is to be enhanced or inriibited. tn trie first case, auto immune diseases, allergic diseases and inflammatory diseases would benefit i~rom such inhibition.
Enhancing the activity of Suppressor T cells would also result in recipient tolerance to a grafted tissue. In the latter case, inhibiting the activity of Supxrressor T
cells would result in greater neutralisation of infectious agents.
_q._ Another object of this invention is a method of screening a vaxiety of compounds, in order to find agonistic and antagonistic compounds capable of enhancing or suppressing the activity of Suppressor T cells. Agonistic and antagonistic compounds would represent alternatives to the monoclonal Antibody to CD47, for example.
DESCRIPTION OF THE INVENTION
This invention will be described hereinbelow, by reference to specific examples, enbodiements and figures, the propose of which is to illustrate the invention rather than to limit its scope.
BRIEF DESCRIPTION OF THE FIGURES
In fig.lA, cells were recovered after 3 days of stimulation., washed , stained with the fluorescent vital dye CFSE and cultured for another 5 days in culture medium supplemented with IL-2. Cells wore then washed and analyzed by flow cytometry . A.s seen, anti-CD47-treated cells (TAS) proliferate much less than the control cells (ThU) activated in the presence of control antibody. Tas and Th0 are comprised of >95% CD3+~
T cells, of which GU% are CD4+ and 40% CDS+.
In fig.l8 and C, TAS and Th0 were expanded in II -2-supplemented medium for 5 days, washed and restimulated with anti-CD3 mAb immobilized on L cells cotransfected vrith human CD32 B7 antigens. After 3 days of culture,the proliferative response was measured by determining the tritiated thymidine uptakes whereas the secretion of IL-10 and TCiF-(3 were measured by ELISA. As seen, TAS proliferate and secrete much less IL-lU than Th0 cells, TAS and ThU produce similar and very low levels of Tf'tF-(3.
Fig.ID, TAS were co-cultured with ThU cells at a 1/1 ratio and the mixture was stimulated for 3 days with graded doses of anti-CD3 mAb (lUU, SU and lU ng%ml) 111i111V17111GG1~ Vll CD32 L37 L 11~.11a1GC:~il.il~J. tia ~GGll, ~rLW J
gJV1.c11Lly L11111171L Lilt ~Jd VIl.rGlA.d.lVd1 and the production of IFN-y by ThU cells.
Fis.lE shov.~s that the suppressive effect ofTAS is dose-dependent.
Fig.2 demonstrates that TAS inhibit the proliferative ( tritiated thymidine uptake) and the cytokine production by Th2 cells (IL-4) (Fig.2A). and Thl cells (Fig.2B and C). Fig.2B
and C also show that the suppressive activity of TAS is not observed if TAS
are physically separated from their target Th0 or Th1 by a semi-permeable membrane.This indicates that the suppressive activity of TAS is contact-dependant and not mediated by soluble factors. Moreover the suppressive activity of TAS is not overcome by blocking anti-IL10 and anti-TGF-(3 mAbs (not shown) Fig.3 shows the phenotype of TAS compared to that of Th0 ~a.s determined by by 2 to 4 color analysis by means of a FACSCALIBUR. TAS and Th0 cells display similar levels of CD25, CD45RO,CD3, CD4, CDR, CD28 and CD47" TAS express higher levels of OX40, GITR and CTLA-4. The proportion of cells expressing membrane bound TGF-(3 is slightly higher in TAS. About 50% of TAS co-express O~i40, GITR and CTLA-4 as compared to about 30% of Th0 cells on which these molecules are also expressed at lower levels-In the experiments summarized in figures 1 to 3, umbilical cord blood mononuclear cells were stimulated in standard conditions with a polyc,lonal activator such as Phytohemaglutinin (PHA) in the presence of a monoclonal antibody to CD47 or a control antibody.
EXAMPLES
Example 1. TAS are prepared from the peripheral blood lymphocytes of a patient with one of the above mentioned inflammatory diseases. The cells are prepared and cultured using conditions similar to those described in Avice et ai. (J.
Irnrnuno1.,2001, 167 : 2459-2468). 10 ~ to 10 g TAS are then re-infused intravenously in the patient. In this example, peripheral blood mononuclear cells are isolated from the patient by conventional fractionation method , Cells are then ac,~tivated for a tear days with a classical T cell activator, such as PHA in the presence of a CD47 ligand, such as for example anti CD47 mAb; cells are then expanded in IL-2 supplemented medium to obtain sufficient number of cells. TAS so prepared are washed and resuspended in a physiological solution before being infi~sed into the patient. The procedure may be repeated as often as necessary.
Example2. The molecular signature of TAS cells, i.e. the genes specifically expressed in these cells and induced by CD47 ligand ,are used to screen any compound with potential application in the treatment of inflammatory disease, CTVHD, graft rejection or cancer.
The genes selectively expressed in TAS cells will be identified on highly purified preparations TAS by means of conventional DNA microarrays.
If a given compound activates a signature gene of TAS, the compound will be examined and tested for its activity in in:f(ammatory diseases ( see above), CrVHD and grad rejection. Such a compound should not be used for the treatment of cancer patient as it will increase the activity of Treg inhibiting the anti-tumor immune response.
Compound inhibiting the expression of TAS signature gene may tested and used as irnmunostimulant to enhance the immune response against cancer cells or any vaccine.
The TAS may be used in assays as they are in a whole blood sample, or in a purified or semi-purified .form e.g. blood cells of a sample would be enriched in CD47 cells, by induction and~or b~~ retention on :ua affinity medium. Such techniques well lrmot~~n in the art, are easily adaptable toCD47 cells. Recombinant cells engineered to express C.D47 could also be used to screen ligands simply having affinity to CD47. A
potentially clinical compound will be developed for its capacity to be an agonistic or an antaganistic to CD47 cell activity.
The invention being hereinabove described, it will be obvious that the same be varied in many ways. Those skilled in the art recognise that other and further changes and modifications may be made thereto without departing from the spirit of the invention, and _7_ it is intended that all such changes and modifications fall within the scope of the invention, as defined in the appended claims.
_g_
Claims (4)
1. A method for interfering with development of a disease or condition involving the activity of Suppressor T cells, in a patient, which comprises the steps of:
- inducing ex vivo the number and/or activity of human regulatory T cells by stimulating blood lymphocytes in the presence of a CD47 ligand; and - reinfusing the induced human regulatory T cells to the patient.
- inducing ex vivo the number and/or activity of human regulatory T cells by stimulating blood lymphocytes in the presence of a CD47 ligand; and - reinfusing the induced human regulatory T cells to the patient.
2. The method of claim 1, wherein the ligand is an agonist of Suppressor T
cells activity.
cells activity.
3. The method of claim 2, wherein the ligand is a CD47 monoclonal antibody.
4. The method of claim 3, wherein the antibody is one produced by the hybridoma deposited at the ATCC under accession number B6H12/Hb9771.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002446391A CA2446391A1 (en) | 2003-10-24 | 2003-10-24 | Method for inducing t cells regulator with cd47 ligands |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002446391A CA2446391A1 (en) | 2003-10-24 | 2003-10-24 | Method for inducing t cells regulator with cd47 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2446391A1 true CA2446391A1 (en) | 2005-04-24 |
Family
ID=34468707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002446391A Abandoned CA2446391A1 (en) | 2003-10-24 | 2003-10-24 | Method for inducing t cells regulator with cd47 ligands |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2446391A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013007933A1 (en) | 2011-07-08 | 2013-01-17 | Universite De Reims Champagne Ardenne | Antagonist peptide of the bond between cd47 and a protein belonging to the thrombospondin family |
US8658159B2 (en) | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
-
2003
- 2003-10-24 CA CA002446391A patent/CA2446391A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8658159B2 (en) | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
US9480715B2 (en) | 2008-06-30 | 2016-11-01 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
WO2013007933A1 (en) | 2011-07-08 | 2013-01-17 | Universite De Reims Champagne Ardenne | Antagonist peptide of the bond between cd47 and a protein belonging to the thrombospondin family |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Romano et al. | Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity | |
Wood et al. | Regulatory T cells in transplantation tolerance | |
Watanabe et al. | CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells | |
Kamimura et al. | Naive CD8+ T cells differentiate into protective memory-like cells after IL-2–anti–IL-2 complex treatment in vivo | |
Shimizu et al. | Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance | |
Skapenko et al. | The IL-4 receptor α-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+ CD4+ regulatory T cells from CD25− CD4+ precursors | |
Rao et al. | Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β | |
Wang et al. | Tim-3-Galectin-9 pathway involves the suppression induced by CD4+ CD25+ regulatory T cells | |
Deknuydt et al. | IL-1β and IL-2 convert human Treg into TH17 cells | |
Asseman et al. | Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10 | |
Minculescu et al. | The role of gamma delta T cells in haematopoietic stem cell transplantation | |
EP1379625B1 (en) | Cd4+cd25+ regulatory t cells from human blood | |
Charbonnier et al. | CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells | |
JP6445437B2 (en) | Method for increasing and evaluating B cells and method for using increased B cells for disease treatment | |
CN107106610A (en) | The composition and method of administration in being treated for adoptive cellular | |
CN108884140A (en) | The Chimerical receptor of modification and compositions related and method | |
CN106535934A (en) | Defined composition gene modified t-cell products | |
AU2002257648A1 (en) | CD4+CD25+ regulatory T cells from human blood | |
US20120269825A1 (en) | Methods of modulating the ox40 receptor to treat cancer | |
WO2007117602A2 (en) | Isolation and use of human regulatory t cells | |
Mutnal et al. | Infiltrating regulatory B cells control neuroinflammation following viral brain infection | |
Horwitz et al. | Therapeutic polyclonal human CD8+ CD25+ Fox3+ TNFR2+ PD-L1+ regulatory cells induced ex-vivo | |
Shinoda et al. | CD30 ligand is a new therapeutic target for central nervous system autoimmunity | |
Yu et al. | Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells | |
Del C Sasiain et al. | Interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |